Highlights

  • RGC closes at USD 16.07 after a 1.1% rise on December 05.
  • Relative strength climbs across 1-month, 3-month, and 6-month periods.
  • Trading volume remains thin with a 10-day Volume Index at or below 0.1.

Regencell Bioscience Holdings Ltd (NASDAQ:RGC) closed at USD 16.07 on December 05, reflecting a rise of 17.0c (1.1%) from the prior session. The move compared with the NASDAQ-100, which added 85.5 points (0.3%) during the day. The stock’s relative price increase of 0.7% against the index placed it ahead of the broader benchmark for the session.

Market Activity and Trading Metrics

RGC recorded 349,993 shares traded, translating to USD 5.6 million in turnover. This figure represented 0.05 times the stock’s average daily volume of 7.1 million shares. Trading has remained subdued over the past ten days, with the Volume Index (VI) at 0.1 or lower, indicating consistently light activity.

Relative strength percentile rankings show upward momentum across periods. The stock stands at 29 for six months, 76 for three months, and 92 for one month. A rise in price alongside rising relative strength is generally viewed as a constructive trend.

Dashboard Snapshot — End of Day, December 05

RGC traded within a 52-week range of USD 9.28c to USD 83.60. The company has a market capitalization of USD 8 billion and 494.38 million shares outstanding. Institutional ownership is low at 0.1% of outstanding shares. The company reported EPS of (0.72c) for FY2025 and ranks 8th out of 310 biotechnology stocks on Nasdaq by market capitalization.

One-Year Price Comparison

One year earlier, the RGC share price was 14.93c. At that time, USD 1,000 would have purchased 6,696 shares. At the December 05 closing price, those shares would be valued at USD 107,605.

Company Overview

Regencell Bioscience Holdings Ltd is engaged in research, development, and commercialization of regenerative cell therapies and bioscience products derived from traditional Chinese medicine. Its programs target neurological and chronic disorders. The company continues work on clinical-stage candidates for central nervous system diseases, including Alzheimer’s and Parkinson’s. Its activities combine traditional herbal knowledge with scientific processes and include expanding collaborations in Asia and advancing regulatory pathways.